Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment

Journal of Proteome Research

Volumn 6, Issue 11, 2007, Pages 4189-4199

  Rozek, Wojciech ^a,d   Ricardo Dukelow, Mary ^a,b   Holloway, Sondra ^a,b   Gendelman, Howard E ^a,b   Wojna, Valerie ^c   Melendez, Loyda M ^c   Ciborowski, Pawel ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS   (Puerto Rico)

^d NATIONAL VETERINARY RESEARCH INSTITUTE   (Poland)

Author keywords

2 dimensional electrophoresis; Cerebrospinal fluid; Cognitive impairment; DIGE; HAD; HIV; Proteomics

Indexed keywords

AMINO ACID SEQUENCE; ARTICLE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AMINO ACID SEQUENCE; BLOTTING, WESTERN; CEREBROSPINAL FLUID; COGNITION DISORDERS; COMPLEMENT C3; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLUORESCENT DYES; GENE EXPRESSION PROFILING; HIV INFECTIONS; HIV-1; HUMANS; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; PROTEOMICS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 36349014934     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr070220c     Document Type: Article

References (51)

1. Navia, B. A.; Rostasy, K. The AIDS dementia complex: clinical and basic neuroscience with implications for novel molecular therapies. Neurotox. Res. 2005, 8(1-2), 3-24.
2. Kramer-Hammerle, S.; Rothenaigner, I.; Wolff, H.; Bell, J. E.; Brack-Werner, R. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res. 2005, 111(2), 194-213.
3. Ances, B. M.; Ellis, R. J. Dementia and neurocognitive disorders due to HIV-1 infection. Semin. Neurol. 2007, 27(1), 86-92.
4. Gendelman, H.; Diesing, S.; Gelbard, H.; Swindells, S. The neuropathogenesis of HIV-1 infection. In AIDS and other manifestations of HIV infection, 4th ed.; Wormser, G., Ed.; Elsevier: Amsterdam, 2004; pp 95-116.
5. Garden, G. A. Microglia in human immunodeficiency virus-associated neurodegeneration. Glia 2002, 40(2), 240-251.
6. Nath, A.; Sacktor, N. Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr. Opin. Neurol. 2006, 19(4), 358-361.
7. Navia, B. A.; Price, R. An overview of the clinical and biological features of the AIDS dementia complex; Oxford University Press: New York, 2005.
8. Janssen, R. S.; Cornblath, D. R.; Epstein, L. G.; McArthur, J.; Price, R. W. Human immunodeficiency virus (HIV) infection and the nervous system: report from the American Academy of Neurology AIDS Task Force. Neurology 1989, 39(1), 119-122.
9. Navia, B. A.; Cho, E. S.; Petito, C. K.; Price, R. W. The AIDS dementia complex: II. Neuropathology. Ann. Neurol. 1986, 19(6), 525-535.
10. Navia, B. A.; Jordan, B. D.; Price, R. W. The AIDS dementia complex: I. Clinical features. Ann. Neurol. 1986, 19(6), 517-524.
11. Ciborowski, P.; Gendelman, H. E. Human immunodeficiency virus-mononuclear phagocyte interactions: emerging avenues of biomarker discovery, modes of viral persistence and disease pathogenesis. Curr. HIV Res. 2006, 4(3), 279-291.
12. Sacktor, N.; Haughey, N.; Cutler, R.; Tamara, A.; Turchan, J.; Pardo, C.; Vargas, D.; Nath, A. Novel markers of oxidative stress in actively progressive HIV dementia. J. Neuroimmunol. 2004, 157(1-2), 176-184.
13. McArthur, J. C.; Letendre, S. L. Is the glass three-quarters full or one-quarter empty? J. Infect. Dis. 2006, 194(12), 1628-1631.
14. Cysique, L. A.; Brew, B. J.; Halman, M.; Catalan, J.; Sacktor, N.; Price, R. W.; Brown, S.; Atkinson, J. H.; Clifford, D. B.; Simpson, D.; Torres, G.; Hall, C.; Power, C.; Marder, K.; McArthur, J. C.; Symonds, W.; Romero, C. Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J. Acquir. Immune Defic. Syndr. 2005, 39(4), 426-429.
15. Gelbard, H. A.; Nottet, H. S.; Swindells, S.; Jett, M.; Dzenko, K. A.; Genis, P.; White, R.; Wang, L.; Choi, Y. B.; Zhang, D., et al. Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin. J. Virol. 1994, 60(7), 4628-4635.
16. Eugenin, E. A.; Gamss, R.; Buckner, C.; Buono, D.; Klein, R. S.; Schoenbaum, E. E.; Calderon, T. M.; Berman, J. W. Shedding of PECAM-1 during HIV infection: a potential role for soluble PECAM-1 in the pathogenesis of NeuroAIDS. J. Leukoc. Biol. 2006, 79(3), 444-452.
17. Cosenza-Nashat, M. A.; Kim, M. O.; Zhao, M. L.; Suh, H. S.; Lee, S. C. CD45 isoform expression in microglia and inflammatory cells in HIV-1 encephalitis. Brain Pathol. 2006, 16(4), 256-265.
18. Brew, B. J.; Pemberton, L.; Blennow, K.; Wallin, A.; Hagberg, L. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology 2005, 65(9), 1490-1492.
19. Jurado, A.; Rahimi-Moghaddam, P.; Bar-Jurado, S.; Richardson, J. S.; Jurado, M.; Shuaib, A. Genetic markers on HIV-1 gp120 C2-V3 region associated with the expression or absence of cognitive motor complex in HIV/AIDS. J. NeuroAIDS 1999, 2(2), 15-28.
20. Roberts, E. S.; Masliah, E.; Fox, H. S. CD163 identifies a unique population of ramified microglia in HIV encephalitis (HIVE). J. Neuropathol. Exp. Neurol. 2004, 63(12), 1255-1264.
21. Silverberg, G. D.; Mayo, M.; Saul, T.; Carvalho, J.; McGuire, D. Novel ventriculo-peritoneal shunt in Alzheimer's disease cerebrospinal fluid biomarkers. Expert Rev. Neurother. 2004, 4(1), 97-107.
22. Simonsen, A. H.; McGuire, J.; Podust, V. N.; Davies, H.; Minthon, L.; Skoog, I.; Andreasen, N.; Wallin, A.; Waldemar, G.; Blennow, K. Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol. Aging 2007.
23. Simonsen, A. H.; McGuire, J.; Hansson, O.; Zetterberg, H.; Podust, V. N.; Davies, H. A.; Waldemar, G.; Minthon, L.; Blennow, K. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch. Neurol. 2007, 64(3), 366-370.
24. Diamandis, E. P. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol. Cell. Proteomics 2004, 3(4), 367-378.
25. Huang, J. T.; Leweke, F. M.; Oxley, D.; Wang, L.; Harris, N.; Koethe, D.; Gerth, C. W.; Nolden, B. M.; Gross, S.; Schreiber, D.; Reed, B.; Bahn, S. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med 2006, 3(11), e428.
26. Fonteh, A. N.; Harrington, R. J.; Huhmer, A. F.; Biringer, R. G.; Riggins, J. N.; Harrington, M. G. Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods. Dis. Markers 2006, 22(1-2), 39-64.
27. Yuan, X.; Desiderio, D. M. Proteomics analysis of phosphotyrosyl-proteins in human lumbar cerebrospinal fluid. J. Proteome Res. 2003, 2(5), 476-487.
28. Yuan, X.; Desiderio, D. M. Proteomics analysis of human cerebrospinal fluid. J. Chromatogr., B: Biomed. Sci. Appl. 2005, 815(1-2), 179-189.
29. Khwaja, F. W.; Nolen, J. D.; Mendrinos, S. E.; Lewis, M. M.; Olson, J. J.; Pohl, J.; Van Meir, E. G.; Ritchie, J. C.; Brat, D. J. Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics 2006, 6(23), 6277-6287.
30. Drabik, A.; Bierczynska-Krzysik, A.; Bodzon-Kulakowska, A.; Suder, P.; Kotlinska, J.; Silberring, J. Proteomics in neurosciences. Mass Spectrom. Rev. 2007, 26(3), 432-450.
31. Thompson, E. J. Proteins of the Cerebrospinal Fluid: Analysis & Interpretation in the Diagnosis and Treatment of Neurological Disease; Academic Press: New York, 2005.
32. Ogata, Y.; Charlesworth, M. C.; Muddiman, D. C. Evaluation of protein depletion methods for the analysis of total-, phospho-and glycoproteins in lumbar cerebrospinal fluid. J. Proteome Res. 2005, 4(3), 837-845.
33. Wittke, S.; Mischak, H.; Waiden, M.; Kolch, W.; Radler, T.; Wiedemann, K. Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches. Electrophoresis 2005, 26(7-8), 1476-1487.
34. Terry, D. E.; Desiderio, D. M. Between-gel reproducibility of the human cerebrospinal fluid proteome. Proteomics 2003, 3(10), 1962-1979.
35. Carey, C. L.; Woods, S. P.; Rippeth, J. D.; Gonzalez, R.; Moore, D. J.; Marcotte, T. D.; Grant, I.; Heaton, R. K. Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin. Neuropsychol. 2004, 28(2), 234-248.
36. Wojna, V.; Skolasky, R. L.; Hechavarria, R.; Mayo, R.; Seines, O.; McArthur, J. C.; Melendez, L. M.; Maldonado, E.; Zorrilla, C. D.; Garcia, H.; Kraiselburd, E.; Nath, A. Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J. Neurovirol. 2006, 12(5), 356-364.
37. Ciborowski, P.; Enose, Y.; Mack, A.; Fladseth, M.; Gendelman, H. E. Diminished matrix metalloproteinase 9 secretion in human immunodeficiency virus-infected mononuclear phagocytes: modulation of innate immunity and implications for neurological disease. J. Neuroimmunol. 2004, 157(1-2), 11-16.
38. Johnson, M. D.; Kim, P.; Tourtellotte, W.; Federspiel, C. F. Transforming growth factor beta and monocyte chemotactic protein-1 are elevated in cerebrospinal fluid of immunocompromised patients with HIV-1 infection. J. NeuroAIDS 2004, 2(4), 33-43.
39. Bandaru, V. V.; McArthur, J. C.; Sacktor, N.; Cutler, R. G.; Knapp, E. L.; Mattson, M. P.; Haughey, N. J. Associative and predictive biomarkers of dementia in HIV-1-infected patients. Neurology 2007, 68(18), 1481-1487.
40. Sporer, B.; Missler, U.; Magerkurth, O.; Koedel, U.; Wiesmann, M.; Pfister, H. W. Evaluation of CSF glial fibrillary acidic protein (GFAP) as a putative marker for HIV-associated dementia. Infection 2004, 32(1), 20-23.
41. Monteiro, de Almeida, S.; Letendre, S.; Zimmerman, J.; Lazzaretto, D.; McCutchan, A.; Ellis, R. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. J. Neuroimmunol. 2005, 169(1-2), 144-152.
42. Gisslen, M.; Hagberg, L.; Brew, B. J.; Cinque, P.; Price, R. W.; Rosengren, L. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J. Infect. Dis. 2007, 195(12), 1774-1778.
43. Perez Laspiur, J. M. S.; Anderson, E. R.; Ciborowski, P.; Wojna, V.; Rozek, W.; Duan, F.; Mayo, R.; Rodriguez, E.; Plaud-Valentin, M.; Rodriguez-Orengo, J.; Gendelman, H. E.; Melendez, L. M. CSF proteomic fingerprints for HIV-associated cognitive impairment. J. Neuroimmunol. 2007, in press.
44. Dubin, G. Proteinaceous cysteine protease inhibitors. Cell. Mol. Life Sci. 2005, 62(6), 653-669.
45. Irani, D. N.; Anderson, C.; Gundry, R.; Cotter, R.; Moore, S.; Kerr, D. A.; McArthur, J. C.; Sacktor, N.; Pardo, C. A.; Jones, M.; Calabresi, P. A.; Nath, A. Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Ann. Neurol. 2006, 59(2), 237-247.
46. Carrette, O.; Demalte, I.; Scherl, A.; Yalkinoglu, O.; Corthals, G.; Burkhard, P.; Hochstrasser, D. F.; Sanchez, J. C. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003, 3(8), 1486-1494.
47. Sanchez, J. C.; Guillaume, E.; Lescuyer, P.; Allard, L.; Carrette, O.; Scherl, A.; Burgess, J.; Corthals, G. L.; Burkhard, P. R.; Hochstrasser, D. F. Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2004, 4(8), 2229-2233.
48. Ciborowski, P.; Kadiu, I.; Rozek, W.; Smith, L.; Bernhardt, K.; Fladseth, M.; Ricardo-Dukelow, M.; Gendelman, H. E. Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome. Virology 2007, 363(1), 198-209.
49. Kadiu, I.; Ricardo-Dukelow, M.; Ciborowski, P.; Gendelman, H. E. Cytoskeletal protein transformation in HIV-1 infected macrophage giant cells. J. Immunol. 2007, 178(10), 6404-6415.
50. Finehout, E. J.; Franck, Z.; Lee, K. H. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis. Markers 2005, 21(2), 93-101.
51. Goldknopf, I. L.; Sheta, E. A.; Bryson, J.; Folsom, B.; Wilson, C.; Duty, J.; Yen, A. A.; Appel, S. H. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Biochem. Biophys. Res. Commun. 2006, 342(4), 1034-1039.